An interventional study of Autohypnosis learning in Colorectal Cancer and Breast Cancer, sponsored by Groupe Hospitalier Mutualiste de Grenoble. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-07.
Sponsored by Groupe Hospitalier Mutualiste de Grenoble · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 583 studies in Colorectal Neoplasms with a site in France — 111 open to participants now, 165 under way, 26 of them phase 3. Colorectal Neoplasms · France.
Among the 583 studies in Colorectal Neoplasms with a site in France, this one is the 256th largest by enrollment of the 464 interventional ones that give a count, is one of 32 that started in 2018, is one of 116 with no phase, and was the 300th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →111 of the 583 studies in Colorectal Neoplasms with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Intercommunal Creteil · Sites in France
Ages 18+
Centre Antoine Lacassagne · Sites in France
Ages 18–75
Verastem, Inc. · Sites in France, United States, Australia and 2 more countries
Ages 18+
University Hospital, Angers · Sites in France
Ages 18+ · Healthy volunteers
EMD Serono Research & Development Institute, Inc. · Sites in France, United States, Argentina and 16 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
583 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 116 · Phase 2 207 · Phase 3 97 · Phase 4 6
First in 1993; this study’s year is marked. 32 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is above the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 152 across the 464 interventional studies, 274 across the 103 observational. Of the 358 that completed or were terminated, 107 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
224 of 583 have an industry lead sponsor. The 10 most frequent:
Groupe Hospitalier Mutualiste de Grenoble is the lead sponsor of 12 studies on the registry; 4 are open to participants now.
Groupe Hospitalier Mutualiste de Grenoble has 1 study filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
38 of the studies in Colorectal Neoplasms with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07520578Phase 3University Hospital, CaenEFFECTIVENESS OF EARLY INFORMATION AND ENDORSMENT BY GP TO INCREASE COLONOSCOPY FOLLOW-UP AND REDUCE DELAYS IN PEOPLE WITH A POSITIVE COLORECTAL CANCER SCREENING TEST. (SUIVICOLO) | 2027-03-24 |
| NCT07116668SafeHeal IncSafeHeal Colovac Anastomosis Protection Device Evaluation Pivotal Study | 2026-12 |
| NCT07151040One-carbon Therapeutics ABPhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors | 2026-12 |
| NCT04585750PMV Pharmaceuticals, IncThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | 2026-12-15 |
| NCT05706779Federation Francophone de Cancerologie DigestiveEncorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer | 2026-12-30 |
Add all 38 to your calendar (.ics) → With an account.
Among the 583 studies in Colorectal Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Therapeutical hypnosis is proven to be an effective medical support to chemotherapy: it was shown that it can reduce the pain, anxiety, fatigue felt by the patient.
Yet, hypnosis requires the presence of an hypnotherapist, which is why auto-hypnosis could be an efficient alternative to handle the side effects of chemotherapy.
In this study, colorectal cancer and breast cancer patients are either taught auto-hypnosis or are taken in standard care for their chemotherapy.
The life quality score (QLQC30) assessed during and after chemotherapies will determine if auto-hypnosis is a good medical support in chemotherapies' adverse effects management.
The proven benefices of auto-hypnosis in the handling of the side effects of chemotherapies could improve the quality of life of cancer affected patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Colorectal or breast cancer history, treated by surgery and that should undergo an chemotherapy
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In this arm, patients are taught autohypnosis during sessions in groups of 3 to 6 with a qualified hypnotherapist. Sessions are set every two weeks, for a total of 6 sessions. Individual sessions are possible for patients who missed a session.
Other: Autohypnosis learning
In this arm, patients are not taught autohypnosis and are treated according to standard of care.
Patients are taught how to do auto-hypnosis by an hypnotherapist before all along their chemotherapy.
>20% increase of the EORTC QLQC30 score (annexe 1) at the third week after the last chemotherapy session in the auto-hypnosis arm compared to the standard care arm.
At the third week after the last chemotherapy session, patients answer the quality of life survey (EORTC QLQC30). Arms' mean score are compared, a minimal difference of 21% is needed for statistical significance.
Time frame: 3 weeks after the last chemotherapy session
Evaluation of auto-hypnosis effects on the life quality and global health of patients at short, mid, and long term.
Patients answer the quality of life survey (EORTC QLQC30) one in two chemotherapy session, or each session for XELOX therapy.
Time frame: 3rd week and 6 month after the last treatment and either one in two chemotherapy sessions, or each chemotherapy session if XELOX treatment
Evaluation of auto-hypnosis effects on different components of quality of life.
Quantitative evaluation of QLQ-C30 subdomains
Time frame: 3rd week and 6 month after the last treatment and either one in two chemotherapy sessions, or each chemotherapy session if XELOX treatment
Evaluation of auto-hypnosis effects on different components of quality of life specific to breast cancer
Quantitative evaluation of QLQ-BR23 scores
Time frame: 3rd week and 6 month after the last treatment and either one in two chemotherapy sessions, or each chemotherapy session if XELOX treatment
Evaluation of auto-hypnosis effects on different components of quality of life specific to colorectal cancer.
Quantitative evaluation of QLQ-CR29 scores
Time frame: 3rd week and 6 month after the last treatment and either one in two chemotherapy sessions, or each chemotherapy session if XELOX treatment
Evaluation of auto-hypnosis effects on drug consumption.
Patients answer a survey about their consumption of different type of drugs : pain-killers, antiemetics, anxiolytics, sleeping drugs.
Time frame: 3rd week and 6 month after the last treatment and either one in two chemotherapy sessions, or each chemotherapy session if XELOX treatment
Evaluation of auto-hypnosis effects on fatigue.
Evaluation of fatigue score MFI-20
Time frame: 3rd week and 6 month after the last treatment and either one in two chemotherapy sessions, or each chemotherapy session if XELOX treatment
Evaluation of auto-hypnosis impact on anxiety and/or depression.
Evaluation of HADS score
Time frame: 3rd week and 6 month after the last treatment and either one in two chemotherapy sessions, or each chemotherapy session if XELOX treatment
Evaluation of auto-hypnosis impact on the global medical handling of their cancer.
Numerical scale of satisfaction survey (from 0 to 10) 0 will mean "very unsatisfied" and 10 will mean "very satisfied".
Time frame: 3rd week and 6 month after the last treatment
Evaluation of patient's satisfaction about auto-hypnosis therapies.
Satisfaction survey about their satisfaction about auto-hypnosis therapies
Time frame: 3rd week and 6 month after the last treatment
Plan to share: No
Ran from May 2018 to primary completion in Jan 2022, 43 months.
Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's 43 months is above that.
Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Groupe Hospitalier Mutualiste de Grenoble